NO20033321L - Androgeniske 7-substituerte 11-halogensteroider - Google Patents

Androgeniske 7-substituerte 11-halogensteroider

Info

Publication number
NO20033321L
NO20033321L NO20033321A NO20033321A NO20033321L NO 20033321 L NO20033321 L NO 20033321L NO 20033321 A NO20033321 A NO 20033321A NO 20033321 A NO20033321 A NO 20033321A NO 20033321 L NO20033321 L NO 20033321L
Authority
NO
Norway
Prior art keywords
androgenic
substituted
steroids
halo steroids
halo
Prior art date
Application number
NO20033321A
Other languages
English (en)
Other versions
NO20033321D0 (no
NO325754B1 (no
Inventor
Rolf Bohlmann
Hermann Kuenzer
Reinhard Nubbemeyer
Dieter Zopf
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20033321D0 publication Critical patent/NO20033321D0/no
Publication of NO20033321L publication Critical patent/NO20033321L/no
Publication of NO325754B1 publication Critical patent/NO325754B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen angår 11 P-halogensteroider med generell formel I, hvorved Rer halogen, X-Y-Z betegner en gruppe med én av de to strukturer CH=C-C eller CH-C=C, og de andre radikaler har den betydning som er angitt i kravene, fremstilling og anvendelse av disse forbindelser for fremstilling av farmasøytiske midler, så vel som farmasøytiske preparater som inneholder 11 P-halogensteroider.
NO20033321A 2001-01-24 2003-07-23 Androgene 7-substituerte 11-halogensteroider, fremgangsmate for fremstilling derav, farmasoytisk preparat inneholdende disse steroider, og anvendelse av disse for fremstilling av farmasoytiske midler NO325754B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10104327A DE10104327A1 (de) 2001-01-24 2001-01-24 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate
PCT/EP2002/000722 WO2002059139A1 (en) 2001-01-24 2002-01-24 Androgenic 7-substituted 11-halogen steroids

Publications (3)

Publication Number Publication Date
NO20033321D0 NO20033321D0 (no) 2003-07-23
NO20033321L true NO20033321L (no) 2003-09-24
NO325754B1 NO325754B1 (no) 2008-07-14

Family

ID=7672351

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033321A NO325754B1 (no) 2001-01-24 2003-07-23 Androgene 7-substituerte 11-halogensteroider, fremgangsmate for fremstilling derav, farmasoytisk preparat inneholdende disse steroider, og anvendelse av disse for fremstilling av farmasoytiske midler

Country Status (35)

Country Link
US (1) US7361645B2 (no)
EP (1) EP1353938B1 (no)
JP (1) JP4339591B2 (no)
KR (1) KR100728088B1 (no)
CN (1) CN1234721C (no)
AR (1) AR053299A1 (no)
AT (1) ATE386045T1 (no)
AU (1) AU2002238516B2 (no)
BG (1) BG66133B1 (no)
BR (1) BR0206653A (no)
CA (1) CA2434187C (no)
CY (1) CY1110377T1 (no)
CZ (1) CZ303553B6 (no)
DE (2) DE10104327A1 (no)
DK (1) DK1353938T3 (no)
EA (1) EA006674B1 (no)
EE (1) EE05274B1 (no)
ES (1) ES2300431T3 (no)
HK (1) HK1064678A1 (no)
HR (1) HRP20030661B1 (no)
HU (1) HUP0303020A3 (no)
IL (2) IL156807A0 (no)
MX (1) MXPA03006578A (no)
NO (1) NO325754B1 (no)
NZ (1) NZ527041A (no)
PE (1) PE20020848A1 (no)
PL (1) PL207582B1 (no)
PT (1) PT1353938E (no)
RS (1) RS50740B (no)
SK (1) SK287444B6 (no)
TW (1) TWI333494B (no)
UA (1) UA75907C2 (no)
UY (1) UY27133A1 (no)
WO (1) WO2002059139A1 (no)
ZA (1) ZA200306537B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
NZ537871A (en) 2002-07-24 2006-10-27 Schering Ag Microbiological processes for the production of 7 alpha-substituted 11 alpha-hydroxy steroids
DE10233723A1 (de) 2002-07-24 2004-02-12 Schering Ag Mikrobiologische Verfahren zur Herstellung von 7α-substituierten 11α-Hydroxysteroiden, daraus herstellbare 7α,17α-substituierte 11β-Halogensteroide, deren Herstellungsverfahren und Verwendung sowie pharmazeutische Präparate, die diese Verbindungen enthalten, sowie daraus herstellbare 7α-substituierte Estra-1,3,5(10)-triene
EP1524983B1 (de) * 2002-07-25 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Zusammensetzung, enthaltend ein androgenes 11-b-halogensteroid und ein gestagen sowie m nnliches kontrazeptivum auf basis dieser zusammensetzung
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
CN106188203B (zh) * 2014-10-08 2017-10-24 常州大学 一种可提高睾酮的收率及大幅减少杂质的合成睾酮方法
TWI530504B (zh) * 2014-12-01 2016-04-21 臺灣永光化學工業股份有限公司 烷基酸睾酮化合物之合成方法
US20220411460A1 (en) * 2021-06-29 2022-12-29 Board Of Regents, The University Of Texas System Modified glucocorticoids

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB863661A (en) * 1958-06-06 1961-03-22 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH380118A (de) * 1959-06-17 1964-07-31 Ciba Geigy Neue Halogenandrostenverbindungen und Verfahren zu deren Herstellung
FR1489519A (fr) * 1965-08-16 1967-07-21 Glaxo Lab Ltd Procédé de préparation de nouveaux 19-nor-stéroïdes et produits obtenus
GB1159434A (en) * 1965-08-16 1969-07-23 Glaxo Lab Ltd 11beta&;-Fluoro-19-nor-Steroids
US3665021A (en) * 1966-07-29 1972-05-23 Glaxo Lab Ltd 9alpha-unsubstituted-11beta-chloro-l9 nos-steroids
GB1260463A (en) * 1968-01-29 1972-01-19 Glaxo Lab Ltd 11beta-BROMO-19-NOR-STEROIDS
DE2410443A1 (de) * 1974-03-01 1975-09-11 Schering Ag 11beta-fluor-androstene
DE2410442A1 (de) * 1974-03-01 1975-09-11 Schering Ag Verfahren zur herstellung von 11-fluorandrostenen
DE3214690A1 (de) * 1982-04-16 1983-10-27 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-chlor-(delta)(pfeil hoch)1(pfeil hoch)(pfeil hoch)5(pfeil hoch)-steroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
US5342834A (en) * 1989-04-07 1994-08-30 The Population Council, Inc. Method for androgen supplementation
US6767902B2 (en) * 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
AU3162200A (en) * 1999-03-08 2000-09-28 Akzo Nobel N.V. 14.beta., 17-alpha-hydroxymethylandrostane derivatives as androgens
AU5209600A (en) * 1999-04-06 2000-10-23 Akzo Nobel N.V. Orally active androgens
DE19959696A1 (de) * 1999-12-08 2001-06-21 Jenapharm Gmbh Ungesättigte 14,15-Cyclopropano-Androstane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
HUP0303020A2 (hu) 2003-12-29
AR053299A1 (es) 2007-05-02
KR100728088B1 (ko) 2007-06-14
CA2434187C (en) 2009-06-16
NZ527041A (en) 2005-02-25
HRP20030661A2 (en) 2005-06-30
HRP20030661B1 (en) 2011-10-31
DE10104327A1 (de) 2002-07-25
HUP0303020A3 (en) 2012-03-28
EA200300756A1 (ru) 2004-02-26
MXPA03006578A (es) 2003-09-22
ATE386045T1 (de) 2008-03-15
DE60224982T2 (de) 2009-04-09
CA2434187A1 (en) 2002-08-01
SK9542003A3 (en) 2003-12-02
BR0206653A (pt) 2004-02-03
BG66133B1 (bg) 2011-06-30
US7361645B2 (en) 2008-04-22
ES2300431T3 (es) 2008-06-16
CN1487950A (zh) 2004-04-07
NO20033321D0 (no) 2003-07-23
DK1353938T3 (da) 2008-05-26
NO325754B1 (no) 2008-07-14
WO2002059139A1 (en) 2002-08-01
ZA200306537B (en) 2004-09-08
IL156807A0 (en) 2004-02-08
PT1353938E (pt) 2008-04-29
EA006674B1 (ru) 2006-02-24
EP1353938B1 (en) 2008-02-13
DE60224982D1 (de) 2008-03-27
EE200300346A (et) 2003-12-15
PL361730A1 (en) 2004-10-04
SK287444B6 (sk) 2010-09-07
CZ20032006A3 (cs) 2004-01-14
YU59403A (sh) 2006-08-17
EE05274B1 (et) 2010-02-15
UY27133A1 (es) 2002-07-31
EP1353938A1 (en) 2003-10-22
TWI333494B (en) 2010-11-21
PL207582B1 (pl) 2011-01-31
KR20030081391A (ko) 2003-10-17
RS50740B (sr) 2010-08-31
JP4339591B2 (ja) 2009-10-07
IL156807A (en) 2008-08-07
AU2002238516B2 (en) 2007-08-23
JP2004517153A (ja) 2004-06-10
CZ303553B6 (cs) 2012-12-05
UA75907C2 (en) 2006-06-15
CY1110377T1 (el) 2015-04-29
CN1234721C (zh) 2006-01-04
HK1064678A1 (en) 2005-02-04
US20050075322A1 (en) 2005-04-07
PE20020848A1 (es) 2002-10-26
BG108023A (bg) 2004-02-27

Similar Documents

Publication Publication Date Title
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
DK1392714T3 (da) Steroider som agonister for FXR
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
WO2003084938A3 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
BRPI0506848A (pt) composto,uso do mesmo, formulação farmacêutica e produto farmacêutico
MXPA03000161A (es) Compuestos novedosos los cuales tienen actividad antiinflamatoria, proceso para su preparacion y composiciones farmaceuticas que las contienen.
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
NO20061045L (no) Imidazolderivater
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
NO20033321L (no) Androgeniske 7-substituerte 11-halogensteroider
DE60336735D1 (de) Neue biologischaktive molekü le
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
YU76500A (sh) Hemijska sinzeza morfolinskih derivata
NO20066011L (no) Merkaptoimidazoler som CCR2-reseptorantagonister
ATE274515T1 (de) Pyrazolopyridinderivate
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
DE60222465D1 (de) Pyrazolopyridin-derivate als antiherpesmittel
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
HUP0302820A2 (hu) CNS rendellenességek kezelésében hasznos indolszármazékok és ezeket tartalmazó gyógyszerkészítmények
NO20055530L (no) NK-2-antagonistiske basiske lineaere forbindelser og preparater som inneholder dem

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees